PDGFRA and gastrointestinal stromal tumor: Overall, in the timeframe of 6–9 months after GIST diagnosis, 27/136 high-risk patients did not receive adjuvant therapy, of which 11 were excluded from the analysis because of the presence of a non-imatinib sensitive mutation (PDGFRA D842V mutation [6/11], KIT and PDGFRA wild-type GIST [5/11]).